ERS International Congress, Milan 2017

Browse by day: Saturday, 09.09.2017 Sunday, 10.09.2017 Monday, 11.09.2017 Tuesday, 12.09.2017 Wednesday, 13.09.2017		Sponsored symposia: Industry Evening Symposium at ERS 2017: “Evolving Concepts in Asthma with Type 2 Inflammation: the Role of Biologics”

Citations should be made in the following way: Authors. Title. Eur Respir J 2017; 50: Suppl. 61, abstract number.

Oral Presentation
Chairs: A. Wells (London, United Kingdom), K. Antoniou (Heraklion, Crete, Greece)

Extracorporeal membrane oxygenation for the treatment of acute exacerbation of interstitial lung diseases S. Ohshimo (Hiroshima, Japan)
Late Breaking Abstract - Six years experience of Pirfenidone treatment in IPF patients in Crete: Real life data K. Karagiannis (Rhodes, Greece)
Patterns of discontinuation in the long-term RECAP study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) U. Costabel (Essen, Germany)
PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients L. Richeldi (Southampton, United Kingdom)
Incidence of multiple progression events in patients with idiopathic pulmonary fibrosis (IPF) in the pooled CAPACITY and ASCEND trials S. Nathan (Falls Church, United States of America)
Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ON B. Crestani (Paris, France)
Effect of nintedanib on composite physiologic index (CPI) in idiopathic pulmonary fibrosis (IPF) A. Wells (London, United Kingdom)